A balanced business driven by focus and execution
41st Annual J.P. Morgan Healthcare
Thierry Bernard
Chief Executive Officer
Disclaimer
Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.
January 9, 2023 | J.P. Morgan Healthcare Conference | 2 |
Our Mission | Our Vision |
Enabling access to valuable | Making improvements |
insights from molecular | in life possible |
research to clinical healthcare |
January 9, 2023 | J.P. Morgan Healthcare Conference | 3 |
Balance: Well-diversified business spanning attractive markets
Diversified
customer base
Well-balanced leadership in
Life Sciences and
Molecular Diagnostics
Broad
geographic reach
>6,300 QIAGENers ensuring
access to attractive markets with
shipments to >170 countries
Highly
recurring revenues
Growing installed base generating demand for high-margin consumables
Life | Molecular | |||
Sciences | Diagnostics | |||
$2.2 | ||||
$1.9 | ||||
$1.5 | 50% | |||
52% | ||||
52% | ||||
48% | 50% | |||
48% | ||||
2019 | 2020 | 2021 |
Net sales (In $ billions at actual rates)
~20%
Asia Pacific | ~45% |
/ Japan | Americas |
~35%
EMEA
~88%
Consumables and related revenues
~12%
Instruments
January 9, 2023 | J.P. Morgan Healthcare Conference | 4 |
Focus: Leveraging a strong core portfolio to drive 5 Pillars of Growth
5 Pillars of Growth
Expanding on solid leadership | Early commercialization phases with strong growth potential | |||
Sample | QuantiFERON | QIAstat-Dx | NeuMoDx | QIAcuity |
technologies | Leading immune | Syndromic testing with | Differentiated microfluidic | Novel microplate digital |
Comprehensive portfolio | response monitoring | unrivaled ease of use | integrated PCR testing | PCR |
(incl. TB) |
Sample technologies | Diagnostic solutions | PCR / Nucleic acid | NGS / Genomics | |
amplification | ||||
2021 | $851 m | $639 m | $434 m | $245 m |
sales | ||||
Core | ||||||||||||||||||
portfolios | Microbiome | Liquid | HID / | Immune | Infectious | Oncology / | OEM Reagents | Universal | QIAGEN | |||||||||
Biopsy | Forensics | response | diseases | Precision | NGS solutions | Digital Insights | ||||||||||||
Medicine |
January 9, 2023 | J.P. Morgan Healthcare Conference | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Qiagen NV published this content on 09 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 15:39:10 UTC.